EGFR and non-small cell lung carcinoma: Indeed, the first-line treatment of advanced NSCLC has evolved from traditional chemotherapy to molecular target and immunotherapy, and the clinical results and use of EGFR-TKIs have significantly improved the overall response rate and progression-free survival of patients with advanced NSCLC (6).